USA, Brisbane-based biotechnology firm, Gate Biosciences, has raised $60 million in Series A funding to support the development of its revolutionary medicines called Molecular Gates. The funding round, led by Versant Ventures and a16z Bio + Health, along with participation from ARCH Venture Partners and GV, will fuel the expansion of operations and research efforts. Gate Biosciences, led by CEO Jordi Mata-Fink, focuses on Molecular Gates, small molecules designed to cure diseases by intercepting harmful extracellular proteins within the cell before they are secreted, offering a promising approach to treat a wide range of illnesses at their source.